STRUCTURED LITERATURE REVIEW OF THE PREVALENCE OF MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORS

被引：0
|
作者：
Lorenzi, M. [1 ]
Amonkar, M. [1 ]
Zhang, J. [1 ]
Mehta, S. [1 ]
Liaw, K. [2 ]
机构：
[1] Precis Xtract, Oakland, CA USA
[2] Merck & Co Inc, N Wales, PA USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.135
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN53
引用
收藏
页码：S22 / S23
页数：3
相关论文
共 50 条
  • [31] Interim analysis of the immune-related endpoints of the mismatch repair deficient/microsatellite instability high (dMMR/MSI-H) and proficient/stable (MMRp/MSS) endometrial cancer cohorts from the GARNET study
    Hanker, L.
    Oaknin, A.
    Gilbert, L.
    Tinker, A., V
    Sabatier, R.
    Boni, V
    O'Malley, D.
    Ghamande, S.
    Duska, L.
    Ghatage, P.
    Sullivan, R. J.
    Moreno, V
    Veneris, J.
    Duan, T.
    Im, E.
    Pothuri, B.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 239 - 240
  • [32] Efficacy and safety of dostarlimab in UK-specific patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) or DNA polymerase epsilon, catalytic subunit (POLε)-mutated solid tumours in the GARNET study
    Samuel, L.
    Miller, R.
    Ross, P.
    Arkenau, T.
    Antony, G.
    Veneris, J.
    Rule, J.
    Starling, N.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S73 - S74
  • [33] Pembrolizumab for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial cancer: Long-term follow-up results from KEYNOTE-158
    O'Malley, D.
    Bariani, G. M.
    Cassier, P. A.
    Marabelle, A.
    Hansen, A. R.
    De Jesus-Acosta, A.
    Miller, W. H.
    Safra, T.
    Italiano, A.
    Mileshkin, L.
    Yao, L.
    Gozman, A.
    Jin, F. J.
    Maio, M.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S796 - S797
  • [34] Tumor-agnostic drug development in dMMR/MSI-H solid tumors
    Bhamidipati, Deepak
    Subbiah, Vivek
    [J]. TRENDS IN CANCER, 2023, 9 (10): : 828 - 839
  • [35] Real-life efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient (dMMR/ MSI-H) biliary tract cancer (BTC)
    le Brun, I. Campo
    Grapinet, E.
    Hollebecque, A.
    Aurillac, V.
    Parent, P.
    Girot, P.
    Gendreau, M.
    Rafert, S.
    Javed, S.
    Touchefeu, Y.
    Roth, G.
    Muller, M.
    Lequoy, M.
    Boileve, A.
    Decraecker, M.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 : S125 - S125
  • [36] Genomic landscapes to characterize mismatch-repair deficiency (dMMR)/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancers stratified by tumor mutation burden (TMB)
    Wang, Jingyuan
    Xiu, Joanne
    Farrell, Alex Patrick
    Battaglin, Francesca
    Arai, Hiroyuki
    Millstein, Joshua
    Soni, Shivani
    Zhang, Wu
    Shields, Anthony F.
    Grothey, Axel
    Weinberg, Benjamin Adam
    Marshall, John
    Lou, Emil
    Khushman, Moh'd M.
    Sohal, Davendra
    Hall, Michael J.
    Oberley, Matthew James
    Spetzler, David
    Lenz, Heinz-Josef
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
    Andre, Thierry
    Shiu, Kai-Keen
    Kim, Tae Won
    Jensen, Benny Vittrup
    Jensen, Lars Henrik
    Punt, Cornelis J. A.
    Smith, Denis Michel
    Garcia-Carbonero, Rocio
    Alcaide, Julia
    Gibbs, Peter
    De la Fouchardiere, Christelle
    Rivera, Fernando
    Elez, Elena
    Bendell, Johanna C.
    Le, Dung T.
    Yoshino, Takayuki
    Zhong, Wen Yan
    Fogelman, David R.
    Marinello, Patricia
    Diaz, Luis A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Combination of nivolumab (nivo) 1 ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study
    Lonardi, S.
    Andre, T.
    Wong, K. Y. M.
    Morse, M.
    McDermott, R.
    Hill, A.
    Hendlisz, A.
    Lenz, H.
    Leach, J.
    Moss, R. A.
    Cao, Z. A.
    Ledeine, J.
    Kopetz, S.
    Overman, M.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 : 3 - 3
  • [39] Management of Microsatellite Instability High (MSI-H) Gastroesophageal Adenocarcinoma
    Zhou, Katherine I.
    Hanks, Brent A.
    Strickler, John H.
    [J]. JOURNAL OF GASTROINTESTINAL CANCER, 2024, 55 (02) : 483 - 496
  • [40] Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors
    Li, J.
    Xu, Y.
    Zang, A.
    Gao, Y.
    Gao, Q.
    Zhang, Y.
    Wang, D.
    Xu, J.
    Yuan, Y.
    Jiang, H.
    Ying, J.
    Shi, C.
    Deng, Y.
    Wang, J.
    Liu, T.
    Huang, Y.
    Shi, M.
    Wang, K.
    Hu, H.
    Shen, L.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S640 - S640
12345